Pfizer Inc. PFE, -1.65% said Friday the U.S. Food and Drug Administration has approved its migraine nasal spray Zavzpret. The treatment is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray that treats acute migraine in adults, the company said in a statement. A Phase 3 study of Zavzpret found it was statistically superior to placebo on both primary endpoints of pain freedom and freedom from most symptoms at two hours after a dose. The study found it offered pain relief as soon as 15 minutes in a secondary endpoint compared with placebo. Pfizer said it will continue to grow its migraine franchise, which includes therapies acquired via the purchase of Biohaven Pharmaceutical last year. Pfizer stock has fallen 19.8% in the last 12 months ,while the S&P 500 SPX, -1.85% has fallen 8%.
This article was originally published by Marketwatch.com. Read the original article here.
